Lördag 16 Maj | 11:00:43 Europe / Stockholm

Svenska | English

Regeneron

Filter

År

Typ

Språk

Rensa

2026-05-16 02:19:44 Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

2026-05-15 20:09:52 Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair 694,25 USD | -3,10%

2026-05-08 13:00:00 Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years 714,16 USD | +0,61%

2026-05-05 13:00:00 Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

2026-04-29 12:30:00 Regeneron Reports First Quarter 2026 Financial and Operating Results 676,28 USD | -8,37%

2026-04-23 21:46:16 Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S. 740,00 USD | -0,56%

2026-04-23 18:40:00 Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S. 740,00 USD | -0,56%

2026-04-22 23:30:00 Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU) 740,00 USD | -0,56%

2026-04-21 16:30:00 Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial 744,67 USD | -0,87%

2026-04-20 22:05:00 Regeneron Announces Investor Conference Presentations 751,17 USD | -0,04%

2026-04-13 12:30:00 Regeneron and Telix Announce Strategic Radiopharma Collaboration 754,63 USD | +1,94%

2026-04-13 07:00:00 Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) 754,63 USD | +1,94%

2026-04-02 22:30:00 Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions 748,53 USD | -3,14%

2026-04-02 18:00:00 EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) 748,53 USD | -3,14%

2026-03-25 21:05:00 Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026 749,26 USD | +1,12%

2026-03-24 07:00:00 Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP) 740,98 USD | +0,46%

2026-03-11 02:29:56 Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment 775,68 USD | -0,17%

2026-03-09 12:00:00 Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients 773,79 USD | +2,22%

2026-03-05 22:05:00 Regeneron Announces Investor Conference Presentation 764,66 USD | -2,56%

2026-02-27 13:00:00 Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment 786,00 USD | +2,82%

2026-02-26 18:00:00 Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders 764,47 USD | -2,15%

2026-02-24 15:30:00 Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS) 777,17 USD | -1,25%

2026-02-19 13:00:00 Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) 779,90 USD | -1,48%

2026-02-11 22:05:00 Regeneron Announces Investor Conference Presentations 776,45 USD | +1,68%

2026-02-10 13:00:00 Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy 763,64 USD | -1,91%

2026-02-02 13:00:00 EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases 752,31 USD | -0,02%

2026-01-30 12:30:00 Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results 752,46 USD | +0,76%

2026-01-21 18:00:00 Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search 737,67 USD | +1,05%

2026-01-02 22:05:00 Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026 776,55 USD | +0,33%

2025-12-23 07:00:00 Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma 784,37 USD | +0,61%

2025-12-22 22:05:00 Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference 779,63 USD | +1,41%

2025-12-07 22:30:00 Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

2025-11-25 07:00:00 Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU) 782,76 USD | +3,23%

2025-11-19 22:10:00 EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications 705,49 USD | -2,13%

2025-11-19 13:00:00 Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation 705,49 USD | -2,13%

2025-11-13 13:00:00 Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs 704,81 USD | +2,76%

2025-11-08 16:46:31 Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

2025-11-07 14:00:00 Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review 648,75 USD | -0,06%

2025-11-03 22:05:00 Regeneron Announces Investor Conference Presentations 632,26 USD | -2,75%

2025-10-31 12:00:00 Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award 650,11 USD | -0,94%

2025-10-28 11:30:00 Regeneron Reports Third Quarter 2025 Financial and Operating Results 644,39 USD | +10,82%

2025-10-17 13:30:19 Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation 577,72 USD | +1,62%

2025-10-15 13:00:41 Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers 579,55 USD | +2,16%

2025-10-12 16:18:30 DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

2025-10-08 20:31:53 Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation 586,30 USD | -0,46%

2025-09-30 22:05:00 Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 570,34 USD | +1,88%

2025-09-26 13:00:42 Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol 559,39 USD | -0,12%

2025-09-22 06:29:00 Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion 594,99 USD | -0,32%

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Regeneron

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden